Armenia vs Lao People's Democratic Republic: Previously treated cases tested for RR-/MDR-TB
Armenia
100.0%
in 2024
Lao People's Democratic Republic
100.0%
in 2024
Armenia rank
1st
Lao People's Democratic Republic rank
1st
Previously treated cases tested for RR-/MDR-TB over time
- Armenia
- Lao People's Democratic Republic
How they compare
Armenia currently reports 100.0% against 100.0% in Lao People's Democratic Republic, a difference of 0.0%.
The two have swapped places 4 times across 13 shared years of data; in 2012 it was Lao People's Democratic Republic ahead.
Armenia ranks 1st and Lao People's Democratic Republic ranks 1st of 180 countries.
Lao People's Democratic Republic has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Armenia | Lao People's Democratic Republic | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 43.9% | 50.5% | 6.6% | Lao People's Democratic Republic |
| 2020s | 98.4% | 100.0% | 1.6% | Lao People's Democratic Republic |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher previously treated cases tested for rr-/mdr-tb, Armenia or Lao People's Democratic Republic?
- Armenia, at 100.0% against 100.0% in Lao People's Democratic Republic as of 2024.
- What is the difference in previously treated cases tested for rr-/mdr-tb between Armenia and Lao People's Democratic Republic?
- 0.0%, with Armenia ahead.
- How many years of comparable data are there for Armenia and Lao People's Democratic Republic?
- 13 years are reported by both, from 2012 to 2024.
- How do Armenia and Lao People's Democratic Republic rank globally for previously treated cases tested for rr-/mdr-tb?
- Armenia ranks 1st and Lao People's Democratic Republic ranks 1st of 180 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Previously treated cases tested for RR-/MDR-TB (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.